Literature DB >> 11212071

Polycystic ovarian disease: heritability and heterogeneity.

P G Crosignani1, A E Nicolosi.   

Abstract

The polycystic appearance of the ovary is the distinguishing characteristic of polycystic ovary syndrome (PCOS) but there is a wide range of other clinical and biochemical features, e.g. elevated serum concentrations of androgens, insulin, LH and decreased insulin sensitivity. The high prevalence of affected individuals and the wide range of related phenotypes can be explained by the interaction of a small number of key genes with environmental factors. Heritability of PCOS has been inferred from studies of the syndrome in various populations (ethnic groups, twins and PCOS families). The data suggest that the condition is passed down through either sex, according to an autosomal dominant model of genetic transmission. To date, specific gene mutations affecting androgen synthesis, insulin secretion and insulin activity explain most of the endocrine and metabolic symptoms, while environmental risk factors (either during prenatal or post-natal life), seem to convert an occult PCOS into a clinically manifest syndrome.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11212071     DOI: 10.1093/humupd/7.1.3

Source DB:  PubMed          Journal:  Hum Reprod Update        ISSN: 1355-4786            Impact factor:   15.610


  13 in total

1.  Associations of adiponectin gene polymorphisms with polycystic ovary syndrome: a meta-analysis.

Authors:  Hongxia Jia; Lili Yu; Xuxiao Guo; Wei Gao; Zhaoshun Jiang
Journal:  Endocrine       Date:  2012-01-22       Impact factor: 3.633

Review 2.  Gestational Hyperandrogenism in Developmental Programming.

Authors:  Christopher Hakim; Vasantha Padmanabhan; Arpita K Vyas
Journal:  Endocrinology       Date:  2017-02-01       Impact factor: 4.736

3.  Developmental programming: excess weight gain amplifies the effects of prenatal testosterone excess on reproductive cyclicity--implication for polycystic ovary syndrome.

Authors:  Teresa L Steckler; Carol Herkimer; Daniel A Dumesic; Vasantha Padmanabhan
Journal:  Endocrinology       Date:  2008-10-30       Impact factor: 4.736

Review 4.  The metabolic effects of drugs used for the treatment of polycystic ovary syndrome.

Authors:  Melia Karaköse; Erman Cakal; Kubilay Ertan; Tuncay Delibaşı
Journal:  J Turk Ger Gynecol Assoc       Date:  2013-09-01

Review 5.  The Role of Genetics, Epigenetics and Lifestyle in Polycystic Ovary Syndrome Development: the State of the Art.

Authors:  Vincenzina Bruni; Anna Capozzi; Stefano Lello
Journal:  Reprod Sci       Date:  2021-03-11       Impact factor: 3.060

6.  Polycystic ovary syndrome resembling histopathological alterations in ovaries from prenatal androgenized female rats.

Authors:  Fang Wang; Bolan Yu; Wenjing Yang; Jianqiao Liu; Jiachun Lu; Xuefeng Xia
Journal:  J Ovarian Res       Date:  2012-05-18       Impact factor: 4.234

7.  Polycystic diseases in visceral organs.

Authors:  Shakila Abdul-Majeed; Surya M Nauli
Journal:  Obstet Gynecol Int       Date:  2011-12-26

8.  Association between circulating adiponectin levels and polycystic ovarian syndrome.

Authors:  Saira Saeed Mirza; Kashif Shafique; Abdul Rauf Shaikh; Naveed Ali Khan; Masood Anwar Qureshi
Journal:  J Ovarian Res       Date:  2014-02-07       Impact factor: 4.234

9.  Effect of auriculotherapy on menstrual irregularities in single girls with polycystic ovarian syndrome and aged 18-35 years in Isfahan in 2012.

Authors:  Mahboubeh Valiani; Imaneh Khaki; Zahra Shahshahan; Mehri Sirus
Journal:  Iran J Nurs Midwifery Res       Date:  2015 Mar-Apr

Review 10.  Epidemiology, diagnosis, and management of polycystic ovary syndrome.

Authors:  Susan M Sirmans; Kristen A Pate
Journal:  Clin Epidemiol       Date:  2013-12-18       Impact factor: 4.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.